Stay updated with breaking news from Multiple Sclerosis Ms. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Inebilizumab is effective for neuromyelitis optica spectrum disorder, even among patients who are genetically at risk for reduced response to anti-CD20 therapies, new research suggests.
Over 25 years of clinical research, phase 3 trials of approved disease-modifying therapies for multiple sclerosis were overwhelmingly made up of White participants, new research shows.
A B-cell count of at least 40/µL is necessary to mount an adequate antibody response to COVID-19 boosters in patients with multiple sclerosis, new research shows.
Patients with MS stable on natalizumab administered every 4 weeks may be able to safely switch to every-6-weeks dosing with no clinically meaningful loss of efficacy.
Data on repair or progression in normal-appearing brain tissue on conventional MRI.